Docstoc

TDap Vaccine Education Tdap Vaccine Postpartum diphtheria

Document Sample
TDap Vaccine Education Tdap Vaccine Postpartum diphtheria Powered By Docstoc
					                                            Tdap Vaccine—Postpartum

      What is the Tdap Vaccine and what does it do?
      It is a vaccine given in a muscle, usually in the arm muscle. It is meant to protect teens and adults from tetanus,
      diphtheria, and pertussis. It allows the body to produce enough antibodies to provide a defense against these three
      diseases. The vaccine does not cause any of these diseases.
           Tetanus—also known as “lockjaw” because it causes spasms in the muscles to the point where a person
               cannot open her mouth or swallow.
           Diphtheria—may cause fatal lung infections but also, in severe cases, causes inflammation in the heart and
               nervous system. This disease can cause damage to the respiratory and nervous systems even to the point
               of death.
           Pertussis—commonly called “whooping cough,” affects the respiratory tract causing coughing fits that can
               disturb normal breathing. Might start out as a regular cold but can last for weeks or months without a
               doctor or nurse realizing that the symptoms are due to pertussis.

      Why am I being offered Tdap Vaccine during my postpartum period?
      The risk for severe and fatal pertussis remains high until an infant has received one to two doses of pediatric
      DTaP (around four months of age). To reduce spreading pertussis to infants, the CDC recommends giving Tdap
      vaccine to women in the postpartum period if they haven't had this vaccine. This dose of Tdap provides active
      booster immunization against tetanus, diphtheria, and pertussis in the mother.
          Routine postpartum Tdap: Pregnant women (including women who are breastfeeding) who have not had
             a dose of Tdap and who have not had a dose of Td within the past two years should receive Tdap after
             delivery and before discharge from the hospital. The dose of Tdap substitutes for the next ten year dose of
             Td.
          CDC also recommends vaccinating other adults at least 2 weeks prior to close contact with infants under
             one year old. Family needs to be informed that they can get Tdap as soon as 2 years after their last tetanus-
             diphtheria shot instead of waiting the usual 10 years, or 5 years if they have a wound.

      What are the most common possible side effects of the Tdap Vaccine?
           Pain, redness, and/or swelling at the injection site
           Other side effects include headache, body ache, tiredness, fever
           These effects usually clear up within a few days. If they continue or become worse, tell your doctor.
            Other effects are possible. Please consult your doctor.

      Who should NOT receive the Tdap Vaccine?
           People who have had allergic reactions to tetanus, diphtheria, or pertussis vaccination should NOT get the
            Tdap Vaccine.
           Anyone who has a severe allergy to any part of the vaccine should NOT get Tdap.
           People who have had a dose of Td (tetanus shot) within the past two years should NOT receive the Tdap
            Vaccine
           People who have been told they had encephalopathy within 7 days of receiving the vaccine (not related to
            other causes)
           People who have a history of Guillan-Barre syndrome within 6 weeks after a previous vaccine, moderate
            or acute illness, history or Arthus reaction to tetanus toxoid or unstable neurological conditions, or—for
            teens—any gradual neurological disorder
           Tdap Vaccine should NOT be given to anyone less than 11 years of age or above 64 years of age.

For CDC’s complete recommendations, please go to following web address: http://www.cdc.gov/mmwr/pdf/rr/rr5704.pdf
For additional vaccine information, please go to the following web addresses:
http://www.fiercebiotech.com/press-releases/fda-approves-glaxosmithkline-tetanus-diphtheria-
http://www.adacelvaccine.com/
http://us.gsk.com/products/assets/us_boostrix.pdf

				
DOCUMENT INFO